Pregabalin for generalised anxiety disorder
Drug and Therapeutics Bulletin, ISSN: 0012-6543, Vol: 48, Issue: 2, Page: 19-22
2010
- 2Citations
- 47Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Generalised anxiety disorder (GAD) is common, with a prevalence of around 4% among adults in the UK. The condition is characterised by chronic excessive anxiety and worry, in combination with a variety of psychological or somatic symptoms. It can be very distressing and disabling and, if left untreated, can be costly to both the individual and society. ▼Pregabalin (Lyrica - Pfizer) is a medicine licensed for GAD in adults. Here we review its role in the management of patients with the problem.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77749292517&origin=inward; http://dx.doi.org/10.1136/dtb.2009.10.0048; http://www.ncbi.nlm.nih.gov/pubmed/20147432; https://dtb.bmj.com/lookup/doi/10.1136/dtb.2009.10.0048; https://dx.doi.org/10.1136/dtb.2009.10.0048; https://dtb.bmj.com/content/48/2/19
BMJ
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know